3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia
9
Leukemia, Myeloid, Acute
7
Hematologic Neoplasms
7
Lymphoma, Non-Hodgkin
6
Lymphoma
6
Primary Immunodeficiency Diseases
3
Multiple Myeloma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Hodgkin Disease
3
Cytopenia
3
Anemia, Aplastic
3
Thalassemia
2
Osteopetrosis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemoglobinopathies
2
Fanconi Anemia
2
Cytokine Release Syndrome
2
Anemia, Sickle Cell
2
Anemia, Diamond-Blackfan
2
Anemia
2
Recurrence
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Interventions
Etoposide
4
pegaspargase
3
Cyclophosphamide
3
Methylprednisolone
2
Gemcitabine
2
Flow Cytometry
2
Dexamethasone
2
Alemtuzumab
2
zanubrutinib
1
sintilimab
1
ruxolitinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Vincristine
1
Thiotepa
1
Th1-Th2 Balance
1
Tacrolimus
1
Rituximab
1
Prednisone
1
Polymerase Chain Reaction
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Methylprednisolone Hemisuccinate
1
Melphalan
1
In Situ Hybridization
1
Immunohistochemistry
1
EPOCH protocol
1
Doxorubicin
1
Cytogenetic Analysis
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphohistiocytosis, Hemophagocytic
×
AP 1903 reagent
×
Lymphoid
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled